Skip to Content

CSL Ltd CMXHF

Morningstar Rating
$185.48 +4.48 (2.47%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

Price
$184.98
Fair Value
$746.86
Uncertainty
Low
1-Star Price
$195.37
5-Star Price
$513.95
Economic Moat
Dhtnw
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CMXHF is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$181.00
Day Range
$185.00185.48
52-Week Range
$144.81207.67
Bid/Ask
$179.30 / $188.15
Market Cap
$89.60 Bil
Volume/Avg
35 / 361

Key Statistics

Price/Earnings (Normalized)
28.84
Price/Sales
6.41
Dividend Yield (Trailing)
1.27%
Dividend Yield (Forward)
1.27%
Total Yield
1.27%

Company Profile

CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world’s second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Large Growth
Total Number of Employees
30,000
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRCvnb$550.4 Bil
VRTX
Vertex Pharmaceuticals IncZpvygf$111.8 Bil
REGN
Regeneron Pharmaceuticals IncFdkrclf$107.9 Bil
MRNA
Moderna IncBtjyr$36.3 Bil
ARGX
argenx SE ADRMdf$23.0 Bil
BNTX
BioNTech SE ADRQxnf$21.6 Bil
ALNY
Alnylam Pharmaceuticals IncFjzrks$19.2 Bil
BMRN
Biomarin Pharmaceutical IncSxprjcr$16.4 Bil
RPRX
Royalty Pharma PLC Class AJjycsg$13.4 Bil
INCY
Incyte CorpXgmldb$13.3 Bil

Sponsor Center